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Abstract 
The incidence of enteric fever caused by Salmonella enterica serovar Paratyphi A (S. Paratyphi A) is 
increasing in many parts of the world. Although there is no major outbreak of paratyphoid fever in 
recent years, S. Paratyphi A infection still remains a public health problem in many tropical 
countries. Therefore, surveillance studies play an important role in monitoring infections and the 
emergence of multidrug resistance, especially in endemic countries such as India, Nepal, Pakistan 
and China. In China, enteric fever was caused predominantly by S. Paratyphi A rather than by 
Salmonella enterica serovar Typhi (S. Typhi). Sometimes, S. Paratyphi A infection can evolve into a 
carrier state which increases the risk of transmission for travellers. Hence, paratyphoid fever is 
usually classified as a “travel-associated” disease. To date, diagnosis of paratyphoid fever based on 
the clinical presentation is not satisfactory as it resembles other febrile illnesses, and could not be 
distinguished from S. Typhi infection. With the availability of Whole Genome Sequencing tech-
nology, the genomes of S. Paratyphi A could be studied in-depth and more specific targets for 
detection will be revealed. Hence, detection of S. Paratyphi A with Polymerase Chain Reaction 
(PCR) method appears to be a more reliable approach compared to the Widal test. On the other 
hand, due to increasing incidence of S. Paratyphi A infections worldwide, the need to produce a 
paratyphoid vaccine is essential and urgent. Hence various vaccine projects that involve clinical 
trials have been carried out. Overall, this review provides the insights of S. Paratyphi A, including 
the bacteriology, epidemiology, management and antibiotic susceptibility, diagnoses and vaccine 
development. 
Key words: Salmonella Paratyphi A, paratyphoid fever, epidemiology, antibiotic resistance, diag-
nosis, vaccine. 
Introduction 
Enteric fever is still an important public health 
problem in many developing countries. It is difficult 
to estimate the real impact of this disease as the clini-
cal symptoms may be confused with other febrile ill-
nesses and specific laboratory confirmation may not 
be available in these areas (1). Enteric fever is a mul-
ti-system disease characterized by prolonged fever, 
sustained blood stream infection, activation of the 
endothelial system, metastatic infections and immu-
nologic complications due to immune complex depo-
sition leading to multi-organ dysfunction (2). Overall, 
enteric fever is caused by Salmonella enterica serovar 
Typhi (S. Typhi) and Salmonella enterica serovar Para-
typhi A (S. Paratyphi A), B and C. However, S. Para-
typhi A has begun to replace S. Typhi as the main 
causative agent of enteric fever in many Asian coun-
tries in recent years. The disease caused by S. Para-
typhi A is well known as paratyphoid fever. The in-
cidence of paratyphoid fever is increasing gradually 
worldwide (3), especially in certain endemic regions, 
such as certain provinces in China and Pakistan where 
S. Paratyphi A infection has become a major health 
problem (4). In 2000, 5.4 million cases of paratyphoid 
fever caused by S. Paratyphi A were estimated (5). 
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The disproportionate increase in the numbers of S. 
Paratyphi A cases may be due to the vaccine effect 
(Ty21a and Vi vaccines), which only protects indi-
viduals from S. Typhi infection (5, 6) and also the in-
appropriate preventive strategies against S. Paratyphi 
A. The reduction strategies that were effective against 
S. Typhi might not be useful against S. Paratyphi A 
(3). 
S. Paratyphi A can be isolated from the blood 
and faeces from paratyphoid fever patients (7). This 
bacterium causes a milder infection with lower mor-
tality and chronic carriage rate compared to S. Typhi 
(8). Transmission of the pathogen is via the fecal-oral 
route, with humans as the sole reservoir of infection. 
Transmission is via consumption of contaminated 
food/water or contact with chronic asymptomatic 
carriers (4). Family contact could be a factor of trans-
mission as well, but a recent report on the risk factors 
for the disease showed that paratyphoid infections 
occur mostly outside the household (9). The im-
portant vehicles of transmission in many countries 
include shellfish harvested from sew-
age-contaminated beds, raw fruits, vegetables ferti-
lized by night soil and eaten raw, milk and milk 
products. Preparation of food by hands of carriers or 
infected food handlers may also contribute to the 
disease transmission (10). 
Symptoms of S. Paratyphi A infection include 
fever, headache, diarrhoea or constipation, malaise, 
anorexia, nausea, dry cough, gastrointestinal symp-
toms, abdominal pain, chills, raised spots or rashes on 
body (9, 11). Overall, the cytokine profile of S. Para-
typhi A infection is similar to S. Typhi but distinct 
from other non-typhoidal Salmonellae. During the 
acute phase of infection, IFN-γ is remarkably induced 
in addition to the increase of IL-6, IL-8, IL-10, IL-15, 
and TNF-α. However, the white blood cell count of 
paratyphoid fever patients does not increase signifi-
cantly during the acute phase as opposed to other 
infectious diseases (12). 
Paratyphoid fever may evolve into a carrier 
state. A carrier state is defined as the shedding of 
Salmonella in the stools or urine after resolution of 
acute illness, while the chronic carrier state is defined 
as the long-term excretion of Salmonella in the stools 
for more than one year and this occurs in less than 5% 
of the patients with enteric fever (8, 13, 14). Chronic 
carriers are at particular risk of transmitting infection 
to others, especially if they are food-handlers (14). The 
identification for persistent excreters of S. Typhi and 
S. Paratyphi A is important to prevent transmission of 
the pathogen to others. However, the excretion of 
pathogenic organisms by chronic carriers may be in-
termittent. So, no practical system of microbiological 
clearance or screening could identify all chronic car-
riers (8). 
Chronic biliary carriage may occur in 2 - 5% of 
cases, even after treatment. Biliary carriage is defined 
as continued shedding of the organism for more than 
a year, and is a public-health risk, especially for in-
fected individuals who work in the food industry (6). 
In this paper, we aimed to provide a better un-
derstanding of S. Paratyphi A, the causative agent of 
paratyphoid fever from the aspects of microbiology, 
genome composition, global trend of epidemiology, 
management, diagnoses and vaccine development. 
Bacteriology 
Generally, S. Paratyphi A is a Gram-negative 
bacterium that belongs to the Enterobacteriaceae family 
(15). Based on the serotyping scheme developed by 
Kauffman-White, S. Paratyphi A is classified as 
serogroup A with an antigenic formula as 1,2,12:a:-. S. 
Paratyphi A (1,2,12:a:-) resembles S. Sendai 
1,9,12:a:1,5) as both are poor Hydrogen Sulfide (H2S) 
producers (7). Howere, they can be distinguished by 
the ability to ferment xylose. According to Edwards 
and Ewing (16), S. Paratyphi A produces a weakly 
positive reaction for H2S test and subsequently fails to 
show evidence of H2S production during the first of 
14 days of incubation. Gas produced by S. Paratyphi 
A is also relatively little and S. Paratyphi A is not ly-
sine decarboxylase-positive organism. (7). 
The Genome features of S. Paratyphi A 
Two genomes of S. Paratyphi A, ATCC 9150 and 
AKU 12601 were sequenced and compared with S. 
Typhi previously by McClelland et al. (17), Didelot et 
al. (18) and Holt et al. (19). The genome size of ATCC 
9150 is 4,585,229 bp encoding 4,263 CDS while 
AKU12601 is 4,581,797 bp in size and encodes for 
4,285 CDS. Both S. Paratyphi A genomes are smaller 
than S. Typhi CT18 and Ty2 (17, 19).  
Both genomes of S. Paratyphi A ATCC 9150 and 
AKU 12601 harbor three phages and 39 inser-
tion/deletion events and 188 SNPs (dN/dS ratio of 
0.62) have been identified (19). Unlike ATCC 9150, 
AKU 12601 harbours a multidrug resistant plasmid, 
IncHI1 which is approximately 212,711 bp. The pres-
ence of plasmids associated with multidrug resistance 
in S. Paratyphi A strains has been reported by Holt et 
al. (19), Mandal et al. (20) and Panigrahi et al. (21). 
Holt et al. (19) reported that the IncHI1 plasmids in S. 
Typhi and S. Paratyphi A are highly similar. This is 
probably due to transfer of plasmids between the two 
serovars (19). Besides that, isolation of cryptic plasmid 
in a clinical strain of S. Paratyphi A was also reported 
by Huang et al. (22).  
Int. J. Med. Sci. 2014, Vol. 11 
 
http://www.medsci.org 
734 
More recently, Liang et al. (23) has sequenced 
five clinical and environmental strains of S. Paratyphi 
A isolated from Zejiang, Guizhou, Jiangxi, Guangxi 
and Yunnan province, respectively. These draft ge-
nomes were compared with the two reference strains, 
ATCC 9150 and AKU12601. In their comparative ge-
nomic analyses, 4252 orthologs have been identified. 
Among the anthologies, 3720 genes were derived 
from core genomes, while 465 genes were dispensa-
ble. Only 67 were strain-specific genes. This suggests 
that the genome of S. Paratyphi A is highly conserved 
(23). However, mutations may have been introduced 
by recombination that favours the adaptation of the 
strains in their ecological niche (18, 23). Most of the 
pseudogene clusters were homologous to functional 
gene clusters and increasing number of pseudogene 
clusters could lead to the inactivation of functional 
genes (23). 
Epidemiology 
S. Paratyphi A is increasingly important as the 
causative agent (50% of Salmonella bloodstream iso-
lates) of enteric fever in Asia (5). It is the second 
leading cause of enteric fever in Asia, the Middle East, 
Africa and South America after S. Typhi (21) (Figure 
1). 
 
 
Figure 1 Distribution of S. Paratyphi A in different countries in Asia and Europe. 
 
South Asia 
In India, no major outbreak of paratyphoid fever 
has been recorded, although it was implicated to 
cause 3% - 17% of enteric fever cases before October 
1995. However, Kumar et al. (24) revealed that among 
the enteric fever cases that occurred in an urban slum 
in New Delhi from October 1995 to October 1996, 25% 
was caused by S. Paratyphi A. Moreover, in 1996, 36 
cases of paratyphoid fever were reported in a resi-
dential area of New Delhi, India within 1 month pe-
riod (September – October) (25, 26). Subsequently, 
infections due to S. Paratyphi A are increasing in In-
dia. A few retrospective cohort studies have been 
conducted in India to monitor the trends of S. Para-
typhi A infection. Based on the data collected by Sood 
et al. (27) from the All India Institute of Medical Sci-
ences in New Delhi, the isolation rate of S. Paratyphi 
A has increased from 6.5% in 1994 to 44.9% in 1998. 
Data from 1999 to 2004 were collected again from the 
same institution by Mohanty et al. (28) and the isola-
tion rate was dropped to 23.8%. More recently, in an-
other study conducted by Capoor et al. (28), a signif-
icant increase in S. Paratyphi A isolation from 2001 to 
2006 has been observed in New Delhi.  
Unusual increase of S. Paratyphi A infection has 
also been observed from other regions of India. For 
example, S. Paratyphi A caused 59% of total enteric 
fever cases in Calicut (now known as Kozhikode) in 
2003 (30), 23.5% in Calcutta from September 2003 to 
August 2004 (3), 40.6% in Chandigarh in 2007 (31), 
20.3% in Mumbai in 2002 (32), 38.4% in Shimla from 
2000 to 2006 (33), 23.3% in Chennai between 
2007-2009, and the isolation rate of S. Paratyphi A in 
Nagpur and Sevagram was 46.2% (34) and 53.3% (35), 
respectively between 2001 to 2003. Moreover, the iso-
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lation of S. Paratyphi A was relatively higher than S. 
Typhi in Bangalore. In the year 2004, 79 S. Typhi and 
170 S. Paratyphi A isolates were isolated from patients 
suffering from enteric fever at the Manipal Hospital 
(36). More recently, a multi-center surveillance study 
has been carried out by the Indian Network for Sur-
veillance of Antimicrobial Resistance Group. A total 
of 764 S. Paratyphi A strains have been isolated be-
tween January 2008 to December 2010 in the 15 par-
ticipating centers throughout India (37).  
S. Paratyphi A infection had emerged in Pakistan 
and Nepal. In Pakistan, there was a significant in-
crease of S. Paratyphi A infection in Rawalpindi (16, 
38) and Karachi since 1996 (3, 39) while in Nepal, a 
higher isolation rate of S. Paratyphi A during summer 
has been documented (40, 41). However, a higher 
prevalence of S. Paratyphi A compared to S. Typhi, 
(with the ratio of 39:30 from a total of 69 isolates) was 
also observed in autumn (September and October) as 
reported by Shirakawa et al. (42). In Patan Hospital, 
Kathmandu, 2677 S. Paratyphi A strains were isolated 
from blood of patients (accounted for 29.3% of enteric 
fever) between 1993 and 2003 (43). Later, during Jan-
uary-August 2004, the isolation rate of S. Paratyphi A 
increased and accounted for 32.8% of enteric fever in 
the same hospital (43). Between June 2005 and May 
2009, the isolation rate of S. Paratyphi A was slightly 
decreased and accounted for 31.5% out of 3,898 cases 
of blood culture-confirmed enteric fever (44). Simi-
larly, 288 out of 541 blood culture samples from pa-
tients with enteric fever collected in Tribhuvan Uni-
versity Teaching Hospital, Kathmandu between Jan-
uary and September, 2004 were serotyped as S. Para-
typhi A (45).  
In Bangladesh, prevalence of paratyphoid fever 
is still not as high as typhoid fever. In Dhaka, Bang-
ladesh, 8 paratyphoid fever cases were detected 
among 48 enteric cases reported for the year 2003 (46). 
In another study carried out by Sheikh et al. (47), only 
5 out of 89 patients with enteric fever were confirmed 
as paratyphoid fever cases. 
East Asia 
In China, the incidence of paratyphoid fever has 
also increased rapidly as reported in San Jiang county 
and Quanzhou county in 1995 (48). The predominance 
of S. Paratyphi A infections has superceded S. Typhi 
in most parts of China. During 1994-2006, a total of 
1855 paratyphoid fever cases were reported by the 
Center for Disease Prevention & Control (GXCDC), 
China. More paratyphoid cases were noticed as com-
pared to typhoid cases from August 2001 to July 2002 
in Heichi City while S. Paratyphi A was responsible 
for all the enteric fevers between April 2006 to De-
cember 2007 in Quanzhou city. In Shenzhen, 70.3% of 
91 patients in Shenzhen People’s Hospital were di-
agnosed with S. Paratyphi A infection (49) during the 
period of 2002 to 2007. Based on the study by Wu et al. 
(49), more paratyphoid fever cases were observed in 
Shenzhen People's Hospital in 2003. In Hong Kong, 
paratyphoid fever was less common than typhoid 
fever. However, the cases of paratyphoid fever have 
exceeded typhoid fever in the year 2003, where 60 
cases of paratyphoid fever were recorded as com-
pared to 49 typhoid fever cases (50). This indicates the 
wide dispersal of S. Paratyphi A in this region during 
2003. 
Southeast Asia 
In Indonesia, S. Paratyphi A is increasingly im-
portant, but the infection rate is still lower than the S. 
Typhi. During August 2002- July 2003 surveillance, 
154 enteric fever cases were reported in Jakarta, but 
only 14% were confirmed as S. Paratyphi A infection 
(3). The same findings were also noted in another 
study by Vollaard et al. (9) which showed more S. 
Typhi than S. Paratyphi A within the period of June 
2001 to February 2003. These studies indicated that S. 
Typhi remains the main cause of enteric fever in Ja-
karta, Indonesia.  
In Singapore, outbreaks of paratyphoid fever 
were mainly due to imported food. In 1979, there 
were 61 laboratory-confirmed S. Paratyphi A cases in 
an outbreak and imported fresh oysters were con-
firmed as the vehicles of transmission (51). The largest 
outbreak happened in 1996 where 167 cases of S. Par-
atyphi A infections were reported between February 
and May where imported de-shelled coconut was 
suspected as the vehicle of transmission (52). During 
the 19 years period (1990-2009), 2464 enteric fever 
cases were notified and among these cases, 707 were 
caused by S. Paratyphi A (259 indigenous cases and 
448 imported cases) (53).  
In Malaysia, the national Salmonella surveillance 
data are collected through passive surveillance of la-
boratory-confirmed human Salmonella isolates. Based 
on the study by Jegathesan (54) and Md. Yasin (55), S. 
Paratyphi A was uncommon compared to S. Typhi. 
However, the number of isolates has increased from 
169 (1973-1982) to 180 (1983-1992).  
Australia 
Since 2003, there was an upsurge in S. Paratyphi 
A infection in Australia. However, the confirmed 
paratyphoid fever cases were often associated with 
travel. Among 810 S. Paratyphi A isolated between 
1985-2010, 547 isolates were originated from India, 
Indonesia, Bangladesh, Pakistan, Nepal, Cambodia, 
Thailand, Philippines, Papua New Guinea and Leba-
non (56). In another study carried out in Sydney, 8 S. 
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Paratyphi A infections were detected during the pe-
riod January–June 2011 and the patients were pre-
dominantly associated with travels to the Indian 
subcontinent (57).  
Europe 
It is undeniable that there is a risk of disease 
transmission across different geographic regions and 
paratyphoid fever is now known as ‘travel-associated’ 
disease (6). Threlfall et al. (58) also cautioned the 
choice of first-line drugs for treatment of infections 
with S. Typhi and S. Paratyphi A in European coun-
tries as treatment failure might occur in patients es-
pecially for those who have a record of travels to areas 
where drug resistant strains are endemic.  
S. Paratyphi A remains the main cause of para-
typhoid fever in England, Wales and Northern Ire-
land and there was an average of 192 paratyphoid 
cases reported each year from 1995 to 2005. In 2005, 61 
cases of S. Paratyphi A infection were associated with 
travels to India, and 31 travels to Pakistan (59). Later, 
between 1 May 2006 and 30 April 2007, 224 S. Para-
typhi A infections have been reported and 100% of the 
patients had travel histories (60). Overall, the rate of S. 
Paratyphi A isolates was slightly higher than S. Typhi 
before 2007, however, S. Typhi has become predomi-
nant since 2008 (ratio of S. Paratyphi A to S. Typhi 
from 2008 to 2012 were 237:268, 185:248, 212:287, 
223:261 and 167:177, respectively) in England, Wales 
and Northern Ireland (60, 61, 62, 63, 64). In France, 
there were only 16 cases of paratyphoid fever caused 
by S. Paratyphi A from 1988 - 1998. Among the 16 
patients, 7 of them had been vaccinated against ty-
phoid fever and this proves that current typhoid vac-
cines might not provide full protection against S. 
Paratyphi A infection (65). 
Management of S. Paratyphi A infection 
and the increase of antibiotic resistance  
Studies on age-related clinical and microbiolog-
ical characteristic of enteric fever have been carried 
out. Walia et al. (66) and Teoh et al. (52) reported 
age-related predilection of paratyphoid fever among 
adults while Khuribulos (67) reported the high prev-
alence of paratyphoid fever among children younger 
than 5 years of age. According to Vollaard et al. (9), 
the age of patients who suffered from paratyphoid 
fever did not differ significantly from typhoid fever 
patients. However, transmission of the pathogen from 
adults to children could occur for those who are ig-
norant of personal hygiene. Therefore, awareness of 
personal and environmental hygiene is very im-
portant, especially in those endemic countries. A 
study to evaluate the effectiveness and efficiency of 
public health management of cases of infection due to 
S. Typhi and S. Paratyphi A from 2002 to 2004 had 
been carried out in Northeast London. No chronic 
carrier of S. Paratyphi A was found. However, the 
current guidelines and practice was not sufficient for 
case follow-up and contact screening (8).  
Today, most paratyphoid fever occurs in less 
developed countries where sanitary conditions re-
main poor and the water supplies are not treated (6). 
Obtaining accurate data on the occurrence of disease 
in these countries is also difficult because the diagno-
sis of paratyphoid fever is often based on clinical as-
sessment, without blood culture confirmation and 
most patients are treated as outpatients (11). In Ja-
karta, Indonesia, over 80% of patients with typhoid or 
paratyphoid fevers are treated as outpatients (9). Most 
of the patients are not aware that they might become 
infected during the first week of convalescence with-
out any symptoms. Without any treatment, the bacte-
ria will remain in one’s body and will be discharged 
for up to three months. Disease transmission can oc-
cur during this period if such infected individuals are 
involved in food handling or lack of personal hygiene 
(4). Sometimes, a patient could be infected by both S. 
Typhi and S. Paratyphi A (68, 69).   
Infections with S. Paratyphi A and S. Typhi are 
commonly treated with ciprofloxacin (70). However, 
increasing multidrug resistant strains of S. Paratyphi 
A and decreasing ciprofloxacin susceptibility have 
been reported since the 1990s (70). S. Typhi and S. 
Paratyphi A with decreased susceptibility to fluoro-
quinolones and resistance to nalidixic acid are com-
monly reported in India, Pakistan, Japan, China and 
Southeast Asia (49, 70, 71, 72, 73). However, nalidixic 
acid and ciprofloxacin resistance was more commonly 
seen in S. Paratyphi compared to S. Typhi (68). Shi-
rakawa et al. (42) had reported a high mutation rate of 
gyrA gene in S. Paratyphi A and such strains are re-
sistant to nalidixic acid. Mutations in the gyrA gene 
that lead to quinolone resistance and reduced suscep-
tibility to fluoroquinolones are clinically significant in 
S. Paratyphi A. Although azithromycin has been 
found to be efficacious for the treatment of uncom-
plicated typhoid fever (74, 75, 76, 77, 78, 79), high 
azithromycin MIC value and a case of azithromycin 
treatment failure in a patient with invasive S. Para-
typhi A infection have been reported (80, 81). 
Clinical presentation and diagnosis of 
paratyphoid fever 
Clinical diagnosis of paratyphoid fever can be 
difficult because the symptoms are not unique and 
overlap with other febrile illness, especially malaria 
and dengue. In addition, both typhoid and paraty-
phoid fever share the same symptoms and it is diffi-
cult to differentiate these two diseases (9). 
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Basically, paratyphoid fever has three clinical 
stages: an early stage marked by high fever; a toxic 
stage with abdominal pain and intestinal symptoms, 
and a long period of recovery stage of fever or defer-
vescence. Toxic stage is the most important stage as 
there is a 1-10% chance of intestinal perforation, 
hemorrhage or inflammatory destruction (9). The in-
fection may develop cardiac complications and some-
times fatal in adults and children (82, 83, 84, 85). Early 
identification of the specific etiological agent and 
knowledge of local antimicrobial resistance patterns 
would be invaluable in guiding rational treatment 
decisions (86). 
In many endemic countries, symptoms or com-
bine-symptoms are the main tools for diagnosis of 
paratyphoid infection. However, a few case studies 
had shown that these symptoms should not be the 
standard for paratyphoid fever’s diagnosis because 
most of these symptoms are too common (87, 88, 89). 
In general, patients with paratyphoid fever have more 
rose spots than patients with typhoid fever. However, 
rose spots are absent sometimes or not apparent in 
dark-skinned patients (9, 88). For example, a man of 
Indian origin was admitted to a hospital in UK be-
cause of fever and severe headache with chills. Dif-
ferential diagnoses were carried out on that patient, 
such as diagnosis for malaria, dengue fever, and 
meningitis. Diagnosis of typhoid or paratyphoid fever 
was not considered because of the absence of rose 
spot. However, growth of S. Paratyphi A in blood 
culture confirmed that the patient was indeed infected 
with S. Paratyphi A (88). 
In general, the mortality and morbidity rates for 
paratyphoid fever are much lower than typhoid fever 
(8, 14). Liver abscesses due to S. Paratyphi are ex-
tremely rare. However, liver abscesses caused by S. 
Paratyphi A infection were reported by Jeans and 
Mckendrick (89). A man who had suffered from 8 
days of serious abdominal pain, fevers, diarrhoea, and 
nausea was admitted to the hospital. Abdominal 
computerised tomography scan result showed a 6 cm 
mass within the right lobe of the liver. Confirmatory 
diagnosis was carried out with serological test and the 
test strongly suggested that the patient had an amoe-
bic liver abscess with secondary infection by S. Para-
typhi A (89). 
Current laboratory detection of S. Para-
typhi A 
Paratyphoid fever could not be distinguished 
clinically from typhoid fever. Consequently, due to 
the limited sensitivity of symptom-combinations, the 
clinical presentation cannot be used as a screening 
method. Laboratory tests are essential for the confir-
mation of paratyphoid fever (9).  
Generally, culture method and serological test 
are the two main conventional laboratory diagnoses 
for S. Paratyphi A. However, in many countries, both 
laboratory methods are combined to identify an in-
fection (38). Firstly, blood samples are collected from 
patients clinically suspected of having typhoid or 
paratyphoid fever. Blood culture is then performed. 
Finally, serological test using patient’s serum is per-
formed to confirm the infection of S. Typhi or S. Par-
atyphi A. The whole process requires more than one 
week for the final identification (38). However, when 
both culture and serology methods are applied, it 
increases the chance of detecting S. Paratyphi A spe-
cifically.  
Culture method 
Culture method is defined as the isolation of a 
bacterium from clinical specimens such as blood, bone 
marrow, stools, urine and intestinal secretions (14). 
Culture method for the detection of S. Paratyphi A is 
similar to other Salmonellae and S. Typhi based on the 
isolation on selective media such as Salmonel-
la-Shigella agar (SS), xylose-lysine-desoxycholate agar 
(XLD) followed by identification using standard bio-
chemical reactions (90). Detection of S. Paratyphi A by 
culture method is time consuming and usually re-
quires 5-11 days (10).  
There are many limitations in culture-based 
methods. The accuracy of diagnosis depends on the 
adequate amount of sample taken from patients, the 
appropriate media to be used, the stage of disease, 
and other variables during the isolation procedure 
(11). In typhoid fever, the number of bacteria is re-
ported to be low in patients’ blood and declined 
within the duration of illness (90), hence the sensitiv-
ity of diagnostic tools is varied during different stages 
of infection. Unlike typhoid fever, the number of 
bacteria throughout the duration of paratyphoid fever 
has not been reported previously. Therefore, this 
makes the diagnosis of paratyphoid fever more chal-
lenging. However, for both typhoid and paratyphoid 
fever, culture from the bone marrow gives the most 
accurate result (76). 
Serological Method 
Serology method is performed for diagnostic 
purposes when an infection is suspected. The widely 
used serological diagnostic modality for typhoid and 
paratyphoid fever is the Widal test which detects an-
tibodies against the O-somatic and H-flagellar anti-
gens (a 4-fold rise between acute and convalescent 
sera) in clinical specimens of suspected patients. It is 
commonly used throughout the world for the diag-
nosis of S. Paratyphi A infection (91). 
However, Widal test is not very accurate and 
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insensitive because of cross-reactivity with other bac-
teria which can also react with the antigens (91, 92). 
Furthermore, individuals who have prior typhoid 
vaccination may also give a false positive result (6). 
Nevertheless, Widal test remains the most widely 
used method for serological diagnosis of paratyphoid 
fever especially in the developing countries because it 
is inexpensive and easy to perform (92, 93).  
More recently, Tam et al. (94) had developed a 
colorimetric test (TUBEX-PA) for paratyphoid fever. 
This test targeted lipopolysaccharides of S. Paratyphi 
A and could produce the result in 5 minutes. How-
ever, this detection system was less sensitive than 
culture-based detection as it could also detect more 
than 50% of typhoid patient in the study conducted 
(94). 
Molecular Method for S. Paratyphi A detection 
McClelland et al. (17) had reported that S. Typhi 
and S. Paratyphi A are genetically identical, and these 
similarities may be exploited to differentiate both in-
fections. By sequencing the genome of S. Paratyphi A 
and comparing it to the genome of S. Typhi, re-
searchers found that the pathogens have evolved 
along similar path. Comparative genomic hybridiza-
tion (CGH) experiments and phylogenetic analysis of 
Salmonella serovars have also demonstrated the ge-
netic relatedness of serovars Typhi and Paratyphi A, 
even though they are members of different 
serogroups (serogroup D1 and A, respectively) (95). 
The advances in molecular biology have con-
tributed greatly to the diagnosis of infectious diseases. 
Techniques which are based on the detection of the 
nucleic acids of pathogens are highly specific and 
sensitive compared to phenotypic methods. There are 
two major molecular approaches used in the detection 
of pathogens, such as nucleic acid hybridization and 
Polymerase Chain Reaction (PCR) (96).  
PCR technique has provided increased sensitiv-
ity, allowed for more rapid processing times and en-
hanced the likelihood of detecting bacterial pathogens 
because it amplifies target DNA sequences that are 
present (86). 
Most of the studies today manage to identify the 
bacteria up to serovar level. PCR technique has also 
been widely applied for the detection of Salmonella 
spp. However, the specific detection for S. Paratyphi 
A is relatively rare compared to S. Typhi. Hirose et al. 
(97) had successfully developed a multiplex PCR, 
which targeted different genes of S. Typhi and S. 
Paratyphi A such as rfbE, rfbS, viaB, and fliC. Tracz et 
al. (95) also developed a genomic approach which is 
able to detect S. Typhi and S. Paratyphi A.  
Ou et al. (98) had successfully developed an al-
ternative multiplex PCR assay to detect S. Paratyphi 
A. This assay was based on bioinformatics-led trans-
lational genomic approach and consists of 4 pairs of 
primers which work together in identifying S. Para-
typhi A and most importantly to distinguish S. Para-
typhi A from S. Typhi and other Salmonella serovars. 
Further evaluation of this assay was carried out by 
Teh et al. (99) and reported that this assay is specific 
for S. Paratyphi A identification. 
Recently, Nga et al. (100) had developed a mul-
tiplex Real-time PCR assay to detect S. Typhi and S. 
Paratyphi A from biological specimens. This multi-
plex real-time PCR was evaluated in blood and bone 
marrow samples. Overall, specificity of this assay on 
various biological specimens is high (100%), however 
limited sensitivity on blood samples was observed. 
Vaccines and future prospect 
In early 1960s, a combined formulated vaccine, 
TAB was used to protect against typhoid and para-
typhoid fever. The efficiency of this vaccine is 90%, 
and the protection period is as long as 5 years. How-
ever, this vaccine has not been widely used (101). In 
the past decades, only Ty21 and Vi polysaccharide 
vaccine that give protection against S. Typhi are 
available (1, 76).  
Typhoid vaccination programs in Thailand, 
China, Vietnam, and India had allowed the emer-
gence and increase of paratyphoid fever (4, 6, 76). For 
example, in Thailand, this vaccination program had 
led to a decrease of S. Typhi but had no effect on S. 
Paratyphi A. Similarly in other parts of the world, the 
disproportionate increase in the numbers of cases of S. 
Paratyphi A may be due to a vaccine effect, which 
gives protection only for S. Typhi (Ty21a and Vi vac-
cines) (4,6).  
The development of vaccine for S. Paratyphi A 
remains a continuous effort. National Institutes of 
Health, Bethesda, MD had developed a new vaccine 
composed of surface-O-specific polysaccharide con-
jugated to tetanus toxoid as described by Konadu et 
al. (102). This vaccine is able to elicit IgG antibodies 
with bactericidal activity in the serum of patients in-
fected with S. Paratyphi A. Field trials were carried 
out in Vietnam targeting all different age groups such 
as adults, teenagers, and 2- to 4-year-old children. As 
the outcome of phase I and II clinical trial were satis-
factory and shown to be safe, a phase III clinical trial is 
planned in China (102).  
On the other hand, Roland et al. (103) and Gat et 
al. (104) have been developing live attenuated S. Par-
atyphi A vaccines as the live attenuated vaccines pro-
vide dosing convenience and the induction of strong 
humoral, mucosal and cellular immunity (103). In the 
study of Gat et al. (104), the role of flagellar protein for 
immunity and protection has been explored while 
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Roland et al. (103) had created phoPQ mutant as 
strong candidates for S. Paratyphi A vaccine. More 
recently, Micoli et al. (105) has described a new con-
jugation chemistry to developed O:2-CRM197-based 
conjugate vaccines. The conjugates, O:2-ADH-SIDEA- 
CRM197 and O:2-CDH-SIDEA-CRM197 are immu-
nogenic in mice and generates good antibodies re-
sponses against S. Paratyphi A.  
Conclusion 
The high prevalence of S. Paratyphi A and the 
emergence of multidrug resistant clone are of great 
concern. Availability of reliable diagnostic tools and 
vaccines undoubtedly will ease the global burden, but 
might not be feasible in countries where a high pro-
portion of people are living in poverty. As the ulti-
mate solution for the prevention and eradication of 
paratyphoid fever, it is essential to improve sanitation 
such as the provision of safe water and food as well as 
enhanced public health awareness. 
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